

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山医药集团股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **APPOINTMENT OF AUTHORISED REPRESENTATIVE**

The board of directors (the “**Board**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) is pleased to announce that Mr. Li Xiaojun (“**Mr. Li**”) has been appointed as an authorized representative (“**Authorised Representative**”) of the Company pursuant to Rule 3.05 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 16 June 2025.

Mr. Li currently serves as the Chairman of the Board of the Company, bringing extensive expertise in corporate management, discipline inspection and supervision, financial and taxation management, resources integration, reform and innovation.

The Board would like to extend its warm welcome to Mr. Li on his new appointment.

Following the appointment of Mr. Li as an Authorised Representative, the authorized representatives of the Company pursuant to Rule 3.05 of the Listing Rules are Mr. Li and Ms. Cheng Ning. The Company has fully complied with Rules 3.05 of the Listing Rules.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 16 June 2025

*As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Ms. Cheng Ning, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.*